logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yanqiu Zhao

Zhengzhou University
H指数:32
被引数:6,822

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world single-center experience

维奈克拉联合阿扎胞苷与低剂量伊达比星和 Ara-C 方案治疗新诊断急性髓系白血病患者的安全性与有效性比较：一项倾向性评分匹配的真实世界单中心研究

Annals of Hematology
IF2.4
2025-12-180
OAAI
Xiao-Tong Chen; Qi Li; Yan-Qiu Zhao; Sheng-Jin Fan
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer

GLORY研究长期随访结果：gumarontinib在MET外显子14跳跃突变的东亚非小细胞肺癌患者中的II期研究

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-09-300
PRE
Lu, Shun; Yu, Yongfeng; Zhou, Jianya; Li, Xingya; Goto, Koichi; Min, Xuhong; Nishino, Kazumi; Cui, Jiuwei; Wu, Ling; Sakakibara, Jun; Shu, Yongqian; Dong, Xiaorong; Li, Lu; Yoneshima, Yasuto; Zhou, Chengzhi; Li, Xiaoling; Zhang, Yiping; Huang, Dingzhi; Zang, Aimin; Zhang, Wei; Wang, Xiuwen; Zhang, Li; Bai, Chong; Fang, Jian; Cao, Lejie; Zhao, Yanqiu; Yu, Yan; Shi, Meiqi; Zhong, Diansheng; Li, Fugen; Duanmu, Wenhao; Wang, Yibin
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial

一线信迪利单抗联合安洛替尼对比化疗治疗转移性非小细胞肺癌的疗效与安全性：一项II期、开放标签、随机对照试验

CANCER COMMUNICATIONS
IF24.9
2025-01-101
OAAI
Chu, Tianqing; Zhong, Hua; Yu, Zhuang; Wang, Jing; Zhao, Yanqiu; Mu, Xiaoqian; Yu, Xinmin; Shi, Xun; Shi, Qingming; Guan, Maojing; Ding, Cuimin; Geng, Nan; Qian, Jialin; Han, Baohui
Real-world effectiveness and safety of fi rst-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)

真实世界中EGFR突变（EGFRm）晚期非小细胞肺癌（NSCLC）患者一线（1L）奥希替尼的有效性与安全性：一项在中国进行的前瞻性、多中心、真实世界研究（FLOURISH研究）

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Zhou, J.; Shen, L.; Lv, D.; Tang, K.; Zhu, D.; Zhao, Y.; Wang, K.; Wang, Y.; Xing, L.; Cui, J.; Ding, L.; Shi, X.; Zheng, J.
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

针对晚期肿瘤患者的PD-1和PD-L1的一流双特异性抗体IBI318 (LY3434172): Ia/Ib期研究

JOURNAL OF HEMATOLOGY & ONCOLOGY
IF40.4
2024-11-290
OAAI
Ruan, Dan-Yun; Wei, Xiao-Li; Liu, Fu-Rong; Hu, Xi-Chun; Zhang, Jian; Ji, Dong-Mei; Huang, Ding-Zhi; Zhao, Yan-Qiu; Pan, Hong-Min; Liao, Wang-Jun; Yang, Kun-Yu; Xu, Nong; Lu, Xiao-Xiao; Chen, Yu-Ling; Zhang, Wen; Zhou, Hui; Zhao, Hong-Yun; Xu, Rui-Hua
Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial

苏鲁法替尼 plus 托瑞帕利姆单抗 combined with 帕emetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Fang, W. F.; Yang, Y.; Huang, Y.; Zhao, Y.; Zhang, Y.; Zhou, T.; Chen, G.; Zhao, S.; Ma, Y.; Hong, S.; Zhao, H.; Zhang, L.

研究方向

暂未获取到该数据
L
Lin Wu
H 指数:59论文数:473被引数:1.7万
J
Jianying Zhou
H 指数:66论文数:860被引数:2.4万
J
Jian Fang
H 指数:35论文数:247被引数:6,361
J
Jianya Zhou
H 指数:22论文数:145被引数:1,954
J
Jun Zhao
H 指数:44论文数:475被引数:1.0万
J
Jiuwei Cui
H 指数:58论文数:641被引数:1.5万
胡
胡祎
H 指数:46论文数:543被引数:1.5万
程
程颖
H 指数:84论文数:1,042被引数:4.5万
H
Hongbo Wu
H 指数:21论文数:104被引数:1,562
Y
Yunpeng Yang
H 指数:47论文数:382被引数:9,351